by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]